The maximum allowable carryover calculation produces a single number, in milligrams, for how much residue of a previous product may remain on shared equipment before the next product is made. Three formulas are in standard use: a dose-based method, a toxicological method built on Permitted Daily Exposure, and a general 10 ppm limit. Run each one that applies to your situation and adopt the lowest result as the governing limit.
Inputs You Need Before You Start
Every version of the calculation draws from the same short list of variables. Pulling them together before you open the formula prevents rework later, because each value has to trace back to an approved source document when an inspector follows the chain.
- Minimum therapeutic dose of the previous product (Product A), taken from approved labeling or the Product Master File.
- Minimum batch size of the next product (Product B). The minimum is used deliberately: a smaller batch concentrates any residue into fewer units, which is the worst case.
- Maximum daily dose of Product B, which maximizes potential patient exposure to any carryover.
- Total shared surface area, in square centimeters, covering every piece of equipment both products contact. Equipment qualification reports usually carry these numbers.
- A safety factor. Its value depends on the method and the potency of the substance, and for dose-based work typically sits between 100 and 1,000.
Safety data sheets add chemical properties like solubility that affect how well cleaning actually removes the residue, which matters when you later translate the MACO into surface-level limits.
The Dose-Based Formula
The dose-based approach is the default when the previous product has a known therapeutic dose. The principle: no patient taking Product B should ingest more than a tiny fraction of a therapeutic dose of Product A. The formula is:
MACO = (Minimum Therapeutic Dose of Product A × Minimum Batch Size of Product B) / (Maximum Daily Dose of Product B × Safety Factor)
For oral solid dosage forms, the safety factor is commonly 1,000, keeping residue exposure below one-thousandth of the minimum therapeutic dose. Injectables and inhalation products warrant more conservative factors because they bypass the digestive tract. FDA cleaning validation guidance requires a scientifically justifiable basis for whatever residue limit a firm sets.1U.S. Food and Drug Administration. Validation of Cleaning Processes (7/93)
A worked example. If Product A has a minimum therapeutic dose of 10 mg, Product B has a minimum batch size of 100 kg and a maximum daily dose of 20 dosage units, and the safety factor is 1,000:
MACO = (10 × 100,000) / (20 × 1,000) = 50 mg
No more than 50 mg of Product A residue may remain across all shared equipment surfaces after cleaning.
The Toxicological (PDE) Formula
When a substance has no clearly defined therapeutic dose, or when it is highly potent, a toxicological method based on Permitted Daily Exposure replaces the dose-based one. The PDE is the maximum amount of a substance a person can be exposed to daily over a lifetime without adverse effects. Some facilities call the same value the Acceptable Daily Exposure (ADE).
The formula is simpler because the safety margin is already inside the PDE:
MACO = (PDE × Minimum Batch Size of Product B) / Maximum Daily Dose of Product B
The PDE itself is derived from the No-Observed-Adverse-Effect Level (NOAEL) in toxicology studies, then adjusted down by five modifying factors covering species differences, individual variability, study duration, severity of toxic effects, and whether a true no-effect level was established.2European Medicines Agency. Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities Each factor ranges from 1 to 10 or 12, so the cumulative adjustment can cut the NOAEL by 100,000-fold or more where safety data is thin. When multiple toxic effects yield multiple PDE values, the lowest one applies.
EMA Guideline EMA/CHMP/CVMP/SWP/169430/2012, effective June 1, 2015, formalized this health-based approach and effectively requires manufacturers in shared EMA-regulated facilities to establish PDE values, moving the industry beyond dose-based and general-limit methods used in isolation.2European Medicines Agency. Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities
The 10 ppm General Limit
The general limit method applies a blanket concentration cap instead of product-specific data. The most common threshold is 10 parts per million, meaning no more than 10 mg of previous-product residue per kilogram of next product. The formula reduces to:
MACO = 0.001% × Minimum Batch Size of Product B
Some facilities use anywhere from 5 to 100 ppm depending on their portfolio, but 10 ppm is the standard default for active pharmaceutical ingredients. This method fills the gap where neither therapeutic dose data nor toxicological data is available, and it also functions as an internal ceiling: many companies cap the final limit at 10 ppm even when dose-based or PDE-based numbers would allow more.
Choosing the Governing Limit
After running every calculation that applies, the facility adopts the lowest result. This is not discretionary. Different methods capture different risk dimensions, and a substance can look safe by one measure while failing another.3A3P Association. Health-Based Approach Implementation for Setting Limits in Cleaning Validation for Vaccines/Biotech
The health-based PDE method sometimes gives a higher, more permissive number than the traditional dose-based or 10 ppm approaches. That is expected. The methods are not supposed to agree; they are supposed to be evaluated together so the most protective one governs. Documenting all applicable calculations side by side, with a stated rationale for the selection, is what gives the final limit scientific credibility during an inspection.
Converting the Total MACO to Swab and Rinse Limits
A total MACO in milligrams is useful for documentation, but analysts test surfaces and rinse water, not batches. The total has to be distributed across the equipment before the lab can compare a sample against it.
Swab Limits
The swab limit is the maximum residue on a defined swab area:
Swab Limit = (MACO / Total Shared Surface Area) × Swab Area
With a 50 mg MACO, 50,000 cm² of shared surface, and a 25 cm² swab, the swab limit is (50 / 50,000) × 25 = 0.025 mg per swab. Samples are typically analyzed by High-Performance Liquid Chromatography (HPLC) and compared to that value.
Recovery matters here. No swab captures 100% of surface residue, so results underestimate what was actually on the equipment. If the validated recovery rate is 80%, that has to be built into how results are interpreted, and recovery should be established experimentally for each product-surface combination during method validation.4National Library of Medicine. Evaluation of Swab and Rinse Sampling Procedures and Recovery Rate Determination in Cleaning Validation
Rinse Limits
Rinse sampling collects a known volume of solvent after it passes over equipment. The rinse limit distributes the total MACO across the surface area, then accounts for the sampled area and the rinse volume. Rinse sampling reaches surfaces swabs cannot, though it gives less location-specific information. Many facilities use swab and rinse methods together.
Visual Cleanliness
Visual inspection is a first-pass check before analytical testing. The general benchmark for visible residue is roughly 4 μg/cm², though experimental data shows most actives, excipients, and formulations become visible well below that: 89% of experimentally determined visible residue limits fell below 2 μg/cm², averaging around 1.1 μg/cm². When calculated swab limits sit above these thresholds, a visually clean surface may already meet acceptance criteria. When calculated limits sit below visible detection, which is common with potent compounds, visual inspection cannot substitute for analytical testing.
Cleaning Agent Residues
The calculation applies to detergents and solvents too, not only product residues. The general industry approach uses one-thousandth of the cleaning agent’s oral LD50 as the starting point for an acceptable daily exposure, then distributes it across batch size and equipment surface area. Because commercial cleaning agents often have high LD50 values, the resulting limits sit above what analytical methods can detect, so most facilities set a practical detection limit of 1 to 10 ppm in the rinse as a conservative default.
When to Recalculate
A validated MACO is not permanent. Any of the following changes invalidates the original number and requires a fresh calculation:
- A new product added to a shared equipment train must be evaluated against every product already validated there. A lower therapeutic dose or smaller batch size can produce a more restrictive limit that supersedes the old one.
- Formulation or dose changes to an existing product alter the variables in the formula.
- Equipment additions, removals, or replacements change the total shared surface area, which shifts swab and rinse limits directly.
- Updated PDE or ADE values from a qualified toxicologist can move the toxicological MACO in either direction.
- Cleaning process changes, including new cleaning agents, altered cycle times, or different rinse procedures, require revalidation.
FDA treats these as validation events, not a separate category of “revalidation.” The standard is the same whether the work is first-time validation or confirming that a change has not compromised an existing one.1U.S. Food and Drug Administration. Validation of Cleaning Processes (7/93)
What Regulators Expect
Federal regulations require equipment to be cleaned at intervals sufficient to prevent contamination that would alter the safety, identity, strength, quality, or purity of a drug product, and written cleaning and maintenance procedures are mandatory.5eCFR. 21 CFR 211.67 – Equipment Cleaning and Maintenance FDA has stated plainly that failure to validate cleaning processes violates Current Good Manufacturing Practice regulations, and cleaning validation is among the most common inspection findings.1U.S. Food and Drug Administration. Validation of Cleaning Processes (7/93)
One practice the agency specifically flags is “test until clean,” where a facility resamples and retests until a passing result appears rather than demonstrating a consistently validated process. FDA treats reliance on that approach as evidence the process itself was never validated.1U.S. Food and Drug Administration. Validation of Cleaning Processes (7/93) Enforcement consequences include Form 483 observations, warning letters, import alerts, and product recalls.
One boundary worth noting: CGMP regulations do not automatically require dedicated equipment for potent compounds like cytotoxics. Manufacturers must identify cross-contamination risks and implement controls, and validated cleaning that reduces residues to safe levels keeps shared equipment permissible.6U.S. Food and Drug Administration. Questions and Answers on Current Good Manufacturing Practice Requirements – Equipment In practice, some compounds have PDE values so low that the MACO cannot be met by cleaning, and dedication becomes the only realistic path.
For EMA-regulated markets, facilities that rely solely on older 10 ppm or 1/1000-of-dose methods without a toxicological assessment may face findings under the 2015 health-based exposure limits guideline, even where the traditional limits happen to be numerically stricter.